We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
Hear from Nicole Mak, a Biology student at Bath University, on her year in industry with Samsara.
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
Our strategy in Samsara is to treat diseases where there is a high unmet need. But we also want to find out how our molecules work to affect healthspan and longevity.
Over the last twenty years or so, the phenomenon of autophagy has become a hot topic in the world of biology.
Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development
Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.
Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
We’re pleased to report that we’ve further strengthened our team in Oxford.
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
Samsara Therapeutics Receives $3.2 Million Seed Funding for Further Pipeline Expansion.